Clinical trials: VITILIGO
Non-segmental Vitiligo
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
The main purpose of this multicenter, randomized, double-blind, placebo-controlled Phase 2b study is to investigate the safety and efficacy of GIA632 in participants with NSV and to identify the optimal dose to be promoted into…
- Trial name
- VITESS (NCT07431177)
- Testing
- GIA632
- Where
- 83 sites in United States, Argentina and 10 more
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Vitiligo
Efficacy and Safety of ACH24 in the Treatment of Vitiligo
This is a multicenter clinical trial, phase III, randomized, placebo-controlled, parallel group, enroll 94 patients, to assess the efficacy of ACH24 in the repigmentation of achromatic areas in patients with vitiligo.
- Trial name
- NCT01419964
- Testing
- Group 01, Group 02
- Where
- Brazil
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo.
- Trial name
- Tranquillo 2 (NCT06072183)
- Testing
- Ritlecitinib
- Where
- 229 sites in United States, Australia and 16 more
- Volunteers
- 1,571 people
- Sponsor
- Pfizer
Vitiligo
Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
- Trial name
- NCT04811131
- Testing
- ARQ-252 cream 0.3%, ARQ-252 Vehicle cream, NB-UVB phototherapy active treatment
- Where
- 5 sites in United States
- Volunteers
- 114 people
- Sponsor
- Arcutis Biotherapeutics, Inc.
Vitiligo
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells.
- Trial name
- Viti-Up (NCT06118411)
- Testing
- Upadacitinib, NB-UVB (narrow-band ultraviolet B) Phototherapy
- Where
- 148 sites in United States, Argentina and 17 more
- Volunteers
- 614 people
- Sponsor
- AbbVie
Vitiligo
Investigating Healthcare Disparities in Vitiligo
Vitiligo is an acquired, non contagious skin disorder characterised by depigmented patches of skin that may appear in a localised or very generalised distribution, and affecting 0.5-2.0% of the global population.There are…
- Trial name
- NCT06097494
- Testing
- No intervention
- Where
- United Kingdom
- Volunteers
- 39,374 people
- Sponsor
- Momentum Data
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
Vitiligo
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
The main objective of this study is to assess the safety, tolerability and efficacy of ATI-50002 Topical Solution, 0.46% in subjects with non-segmental facial vitiligo.
- Trial name
- NCT03468855
- Testing
- ATI-50002 topical solution
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Aclaris Therapeutics, Inc.
Non-Segmental Vitiligo
A Study of VC005 Tablets in Adolescent Subjects With Non-Segmental Vitiligo
This study is a multicenter, open-label, non-randomized study designed to evaluate the pharmacokinetics (PK), safety, and preliminary efficacy of VC005 tablets in adolescent subjects with Non-Segmental Vitiligo
- Trial name
- NCT07828639
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Adult Subjects With Non-Segmental Vitiligo
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in Subjects With Non-Segmental Vitiligo
To evaluate the efficacy of QY201 Tablets in adult subjects with non-segmental vitiligo, and to provide evidence for dose selection in the confirmatory Phase III clinical trial.
- Trial name
- NCT07712523
- Testing
- QY201 Tablets(5mg）, QY201 Tablets（10mg）, QY201 Tablets（20mg）
- Where
- China
- Volunteers
- 200 people
- Sponsor
- E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.
Vitiligo, Atopic Dermatitis
An Observational Study of Patients With Dermatologic Disease
TARGET-DERM+ is an observational research study to conduct a comprehensive review of outcomes for patients with dermatologic disease (DD) and providers who treat these patients.
- Conditions
- Vitiligo, Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa (HS)
- Trial name
- TARGET-DERM+ (NCT07748169)
- Where
- United States
- Volunteers
- 2,000,000 people
- Sponsor
- Target PharmaSolutions, Inc.
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Vitiligo
Clinical Study to Investigate the Safety and Effectiveness of RECELL for Repigmentation of Stable Vitiligo Lesions
This is a prospective blinded within-subject randomized study to evaluate the application of Spray-On Skin™ Cells, prepared using the RECELL® Device for safe and effective repigmentation of ablated stable vitiligo lesions.
- Trial name
- NCT04547998
- Testing
- Control Intervention (UVB), Investigational Interventions (Ablative Laser Resurfacing + RECELL + UVB)
- Where
- 12 sites in United States
- Volunteers
- 25 people
- Sponsor
- Avita Medical
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo
The purpose of this study is to determine whether afamelanotide and narrow band UVB are effective in the treatment of non-segmental vitiligo (NSV).
- Trial name
- NSV (NCT01382589)
- Testing
- Afamelanotide, NB-UVB
- Volunteers
- 15 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech
Vitiligo
A Trial to Test the Safety and Efficacy of TEV-53408 in Participants With Vitiligo
The purpose of the trial is to evaluate the safety of TEV-53408 when given as an under the skin injection to adults with vitiligo. Vitiligo is a condition where patches of skin lose color (pigment) and turn white.
- Trial name
- NCT06625177
- Testing
- TEV-53408
- Where
- 13 sites in United States
- Volunteers
- 66 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Vitiligo
Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)
The purpose of this study was to evaluate the efficacy and safety of afamelanotide, when combined with narrowband ultraviolet B (NB-UVB) phototherapy, in patients with nonsegmental vitiligo.
- Trial name
- NCT04525157
- Testing
- Afamelanotide
- Volunteers
- 21 people
- Sponsor
- Clinuvel Pharmaceuticals Limited
Vitiligo
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
- Trial name
- TONE (NCT05971381)
- Testing
- RECELL® Autologous Cell Harvesting Device
- Where
- 17 sites in United States
- Volunteers
- 109 people
- Sponsor
- Avita Medical
Nonsegmental Vitiligo
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin…
- Trial name
- NCT07108283
- Testing
- Zasocitinib
- Where
- 69 sites in United States, Canada and 7 more
- Volunteers
- 200 people
- Sponsor
- Takeda
Vitiligo
A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face
The CUV104 study will assess the efficacy and safety of afamelanotide in patients with vitiligo on the face and body as a monotherapy in repigmentation.
- Trial name
- NCT05210582
- Testing
- Afamelanotide
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Clinuvel, Inc.